FDA approves a novel drug for schizophrenia

Original Article ↗ Hacker News Discussion ↗

A newly approved schizophrenia drug that targets muscarinic receptors instead of dopamine is being hailed as a potential breakthrough, especially for avoiding the severe side effects of existing antipsychotics. Commenters weigh that promise against a U.S. list price of roughly $22,500 per year, debating whether such pricing is justified by R&D costs, public funding, and the broader structure of the pharmaceutical market. The thread also surfaces deeper fault lines over how scientific and ethical current psychiatric practice is, the role of trauma and social conditions (like homelessness) in severe mental illness, and whether medication-centric approaches can meaningfully improve long‑term outcomes.

Mechanism and Trial Data

  • Drug is a xanomeline/trospium combo: central muscarinic (M1/M4) agonist plus a peripherally acting antagonist to blunt GI and other peripheral side effects.
  • Some find the “agonist + antagonist for same pharmacophore” design elegant; others question whether central analgesic/psychoactive and peripheral effects can really be separated (compared to opioids discussion).
  • Linked trials include short 5‑week efficacy studies and longer 52‑week open‑label safety studies; some commenters want more long‑term outcome data beyond PANSS scores.

Clinical Promise vs. Risks

  • Many see it as a major advance over dopaminergic antipsychotics, which are described as “chemical lobotomy” with weight gain, metabolic issues, movement disorders, and emotional blunting causing non‑adherence.
  • Others stress that “feeling like a different person” is itself a serious harm, not just a trade‑off.
  • There is skepticism that any antipsychotic is benign; concerns about withdrawal, long‑term brain changes, and whether the new drug will mainly sedate rather than treat.

Price, R&D, and Pharma Economics

  • List price $22.5k/year ($1,850/month wholesale) draws criticism, especially vs. expected low manufacturing cost and much lower prices anticipated in Europe/generics.
  • Defenders argue high prices are needed to recoup a $14B acquisition and many failed R&D bets; opponents note the molecule was originally developed cheaply in the UK and that public/taxpayer funding underpins much basic research.
  • Debate over whether 20% profit on successful drugs is sufficient, and whether US overpayment subsidizes global pharma.

Regulation and the FDA

  • Some portray the FDA as captured and over‑lenient with psychiatric drugs; others say it is pushed both to approve “snake oil” and then blamed when it does.
  • Disagreement over whether FDA’s gatekeeping is primarily protecting patients or protecting industry.

Nature of Schizophrenia and Psychiatry

  • Strong clash between:
    • View that schizophrenia is a well‑defined, devastating brain illness where antipsychotics are often life‑saving.
    • View that diagnoses are subjective, DSM is “bible‑like,” and antipsychotics themselves can induce psychosis‑like symptoms, long‑term damage, and reduced lifespan.
  • Some criticize simplistic neurotransmitter stories (e.g., serotonin for depression) and extend that skepticism to this mechanism.
  • Others counter that many chronic diseases require lifelong meds; lack of a “cure” doesn’t invalidate treatment.

Trauma, Psychotherapy, and Alternatives

  • Multiple citations link childhood trauma and interpersonal abuse to higher risk and severity of psychosis, proposing trauma‑focused therapies (e.g., CBT, EMDR) as important, sometimes with reported remission cases.
  • Critics argue schizophrenia is primarily biological, that psychotherapy alone is rarely sufficient, and that telling patients it’s “just trauma” can be harmful.

Homelessness and Social Policy

  • Repeated discussion of homelessness:
    • One camp sees effective antipsychotics as potentially transformative for a substantial subset of chronically homeless people with psychosis.
    • Another stresses that housing, income, and basic healthcare (“housing first”) are prerequisites; drugs alone won’t reach most homeless people or address financial drivers.

Healthcare Systems and Access

  • Extensive back‑and‑forth on US vs. public systems:
    • Some defend high US prices as fueling global innovation.
    • Others note worse US health outcomes and argue for nationalized or heavily regulated healthcare and price controls.
  • Concern that homeless and poor patients will be last to benefit, waiting for generics.

DIY, Generics, and Grey‑Market Access

  • A few mention buying raw chemicals by CAS number or compounding to bypass pricing, which others call dangerous and irresponsible.
  • Some hope for generics in Europe at very low cost; others mention “pharma hacking” collectives, raising safety and regulatory questions.

Vitamins and Non‑Mainstream Claims

  • One commenter asserts schizophrenia can be cured with niacin; others rebut that megavitamin therapy hasn’t held up under replication, while acknowledging micronutrient deficiencies (e.g., B6, C) can influence mood and cognition.

Lived Experience and Medication Adherence

  • Several share personal or family stories:
    • Catastrophic outcomes when people stop meds due to side effects or lack of insight (anosognosia).
    • Others report severe harms from meds and better functioning after tapering off, fueling distrust of psychiatry.
  • Tension between calls for long‑acting injectables and more coercive treatment vs. strong emphasis on autonomy and personalized, non‑pharma‑dominated care.